Cedar Ridge Clinical Research Institute

Research Site 0142 · 1400 Cedar Ridge Parkway, Suite 220, Fairhaven, ST 58027
Study coordinator 555-0184 (Mon–Fri 8:00 a.m.–5:00 p.m.) · 24-hour study line 555-0188
Sponsor: Vantera Therapeutics, Inc. · Protocol VTX-1042-301

PARTICIPANT VISIT CALENDAR

Calendar version
2.1, dated 14 January 2027
Derived from
Protocol VTX-1042-301 v3.0 (09 Dec 2026)
IRB approved
06 February 2027 · expires 05 February 2028
IRB protocol
MC-2027-0184 · Site 0142

Your Research Visit Calendar

Schedule of activities for protocol VTX-1042-301, written out visit by visit with every window, fasting requirement, and specimen

EVERY WINDOW IS COUNTED FROM DAY 1 — NOT FROM YOUR LAST VISIT

If a visit lands late inside its window, the next visit is still scheduled from Day 1. Call the coordinator at 555-0184 before a window closes; a missed window is a protocol deviation that has to be reported.

PARTICIPANT ID	DAY 1 DATE	TREATMENT PERIOD	TOTAL STUDY CONTACTS
VTX-1042-301-0142-0037	**Monday, 15 March 2027**	**52 weeks**	**14 (11 in person, 2 telephone, 1 either)**
PRINCIPAL INVESTIGATOR	STUDY COORDINATOR	24-HOUR STUDY LINE	MAXIMUM VISIT REIMBURSEMENT
Imogen T. Race, MD	**Naomi Ellsworth, CCRC · 555-0184**	**555-0188**	**12 × $75.00 = $900.00, plus mileage**

VISIT CALENDAR WITH WINDOWS

VISIT	PROTOCOL WINDOW	TARGET DATE	EARLIEST	LATEST	FORMAT	FASTING	REIMBURSEMENT
V1 · Screening	Day –28 to Day –1	24 Feb 2027	15 Feb 2027	14 Mar 2027	In person, ≈4 h	Yes, 8 h	$75.00
V2 · Baseline and randomization	Day 1, no window	15 Mar 2027	15 Mar 2027	15 Mar 2027	In person, ≈5 h	Yes, 8 h	$75.00
V3 · Week 2	Day 15 ± 3 days	29 Mar 2027	26 Mar 2027	1 Apr 2027	In person, ≈2 h	No	$75.00
V4 · Week 4	Day 29 ± 3 days	12 Apr 2027	9 Apr 2027	15 Apr 2027	In person, ≈2 h	No	$75.00
P1 · Week 6 telephone	Day 43 ± 3 days	26 Apr 2027	23 Apr 2027	29 Apr 2027	Telephone, ≈20 min	No	$0.00
V5 · Week 8	Day 57 ± 5 days	10 May 2027	5 May 2027	15 May 2027	In person, ≈2 h	No	$75.00
V6 · Week 12	Day 85 ± 5 days	7 Jun 2027	2 Jun 2027	12 Jun 2027	In person, ≈4 h	Yes, 8 h	$75.00
P2 · Week 16 telephone	Day 113 ± 5 days	5 Jul 2027	30 Jun 2027	10 Jul 2027	Telephone, ≈20 min	No	$0.00
V7 · Week 20	Day 141 ± 7 days	2 Aug 2027	26 Jul 2027	9 Aug 2027	In person, ≈2 h	No	$75.00
V8 · Week 26	Day 183 ± 7 days	13 Sep 2027	6 Sep 2027	20 Sep 2027	In person, ≈4 h	Yes, 8 h	$75.00
V9 · Week 34	Day 239 ± 7 days	8 Nov 2027	1 Nov 2027	15 Nov 2027	In person, ≈2 h	No	$75.00
V10 · Week 42	Day 295 ± 7 days	3 Jan 2028	27 Dec 2027	10 Jan 2028	In person, ≈2 h	No	$75.00
V11 · Week 52, end of treatment	Day 365 ± 7 days	13 Mar 2028	6 Mar 2028	20 Mar 2028	In person, ≈5 h	Yes, 8 h	$75.00
V12 · Safety follow-up	Day 395 ± 7 days	12 Apr 2028	5 Apr 2028	19 Apr 2028	Telephone or in person	No	$75.00 if in person

Target dates are calculated from Day 1 = 15 March 2027. The screening visit shown as completed on 24 February 2027 sat inside the Day –28 to Day –1 window. Reimbursement totals $825.00 across the eleven scheduled in-person visits, or $900.00 if the safety follow-up is done in person.

WHAT HAPPENS AT EACH VISIT

ASSESSMENT OR PROCEDURE	SCR	D1	W2	W4	P6	W8	W12	P16	W20	W26	W34	W42	W52	SFU
Informed consent, before any study procedure	X													
Eligibility and entry criteria review	X	X												
Medical history and demographics	X													
Physical examination	X	X					X			X			X	
Vital signs, height, and weight	X	X	X	X		X	X		X	X	X	X	X	X
12-lead electrocardiogram	X	X					X			X			X	
Fasting chemistry panel (8-hour fast)	X	X					X			X			X	
Hematology and urinalysis	X	X		X			X			X		X	X	
Pregnancy test, if applicable	X	X		X		X	X		X	X	X	X	X	
Pharmacokinetic blood sample		X	X				X			X				
Optional biomarker sample (separate consent)		X					X						X	
Study drug dispensing		X		X			X		X	X	X	X		
Study drug return and accountability			X	X		X	X		X	X	X	X	X	
Electronic diary review		X	X	X	X	X	X	X	X	X	X	X	X	X
Side effect and other-medication review	X	X	X	X	X	X	X	X	X	X	X	X	X	X
Paper questionnaires completed at the site		X					X			X			X	
Visit reimbursement record signed	X	X	X	X		X	X		X	X	X	X	X	

Scr = screening · D1 = baseline and randomization · W = week visit in person · P = telephone visit · SFU = safety follow-up. An X means the item is scheduled for that contact. Items may also be repeated at an unscheduled visit when the investigator asks for one.

RULES THAT GOVERN THE WINDOWS

1. Every window is counted in days from Day 1, which is 15 March 2027 for you.
2. A visit completed anywhere inside its window is on time. There is no advantage to the target date itself.
3. The Day 1 visit has no window. It happens on the day it is scheduled or it is rescheduled entirely.
4. Windows never shift because an earlier visit ran late. The schedule does not drift.
5. If a window is going to be missed, call 555-0184 before it closes so the site can document it correctly.
6. A missed window is recorded as a protocol deviation. It is reported to the IRB and the sponsor; it is not a reason to leave the study.

FASTING, MEDICATIONS, AND WHAT TO BRING

- Fasting visits require 8 hours with nothing but water. They are marked in the calendar: screening, Day 1, Week 12, Week 26, and Week 52.
- Water is encouraged during the fast. Do not skip a prescribed medicine to fast — call 555-0184 and the visit will be rescheduled or the timing adjusted by the investigator.
- Bring all study drug containers, used and unused, to every visit marked for return and accountability.
- Bring the diary device charged, and a current list of every medicine and supplement you are taking.
- Bring your reimbursement card and a parking ticket to validate.
- Allow the full time listed in the Format column. Visits marked ≈4 h and ≈5 h are long because of the fasting draws and the electrocardiogram.

SPECIMENS COLLECTED AND WHAT THEY ARE USED FOR

SPECIMEN	COLLECTED AT	APPROXIMATE VOLUME	USED FOR
Fasting chemistry panel	Scr, D1, W12, W26, W52	8 mL	Safety monitoring of liver and kidney values
Hematology and urinalysis	Scr, D1, W4, W12, W26, W42, W52	6 mL blood, urine sample	Safety monitoring of blood counts
Pregnancy test	Scr, D1, W4, W8, W12, W20, W26, W34, W42, W52	Urine sample	Required safety check where applicable
Pharmacokinetic sample	D1, W2, W12, W26	4 mL	Measuring how much study drug is in the blood
Optional biomarker sample	D1, W12, W52	10 mL	Exploratory research under a separate optional consent. Declining does not affect your participation or any other part of the study.

The largest single draw, at Day 1, is about 28 mL — roughly two tablespoons. Tell the coordinator if you have had trouble with blood draws before.

UNSCHEDULED VISITS

An unscheduled visit can be added at any point in the study. It does not replace a scheduled visit and it does not change any window.

- Requested by the investigator to follow up a symptom or a laboratory value
- Requested by you through the coordinator at 555-0184
- Reimbursed at the same $75.00 rate when it is in person
- Recorded separately in the study record with its own date and reason

REIMBURSEMENT RECORDS

ITEM	AMOUNT	HOW IT IS PAID
Completed in-person visit	$75.00	Reloadable card, within 10 business days
Telephone visit	$0.00	Not reimbursed
Mileage	$0.55 per mile	Reloadable card, with the signed visit record
Parking	Validated at the visit	No claim needed

You sign a reimbursement record at each in-person visit. Payments may be reportable income; the site can provide a summary of amounts paid on request.

Consent boundary: Any video, animation, slide, handout, or plain-language summary prepared from this document — including the demonstration video this specimen was built for — **supplements the informed consent discussion and never replaces it**. No material of any kind replaces the conversation with the study team or the signed, IRB-approved consent form. If a summary and the IRB-approved consent form disagree, the consent form controls.

Scope of this document: This calendar is a convenience copy of the schedule of activities in protocol VTX-1042-301 version 3.0. It does not state eligibility, and nothing in it means you are or will be enrolled — eligibility is determined only by the investigator against the protocol criteria. If this calendar and the protocol or the signed consent form disagree, the protocol and the consent form control.